budesonide (Takeda, 25ee90)

Budesonide is a potent synthetic glucocorticoid corticosteroid with high topical anti-inflammatory activity and low systemic bioavailability due to extensive first-pass metabolism. In the treatment of eosinophilic esophagitis (EoE), budesonide is formulated to provide targeted delivery to the esophageal mucosa to reduce eosinophilic infiltration and inflammation. The most notable formulation for this indication is **Eohilia** (TAK-721), a mucoadherent oral suspension originally developed by Shire and later by Takeda, which received FDA approval in 2024. Another formulation, **Jorveza**, is an orally disintegrating tablet (ODT) developed by Dr. Falk Pharma and approved in several regions including Europe and Canada. While the provided context associates budesonide with Adare Pharmaceuticals and the FLUTE trial, that trial (NCT03133299) actually investigated **APT-1011**, which is a formulation of **fluticasone propionate**, not budesonide. The confusion likely arises from a labeling error in certain clinical trial records or the shared therapeutic class and indication of these two corticosteroids.

Brand names

EohiliaJorveza

Other names

Budesonide Oral SuspensionBOSOral Budesonide SuspensionOBSOral Viscous Budesonide